Osteonecrosis due to drugs, multiple sites
ICD-10 M87.19 is a billable code used to indicate a diagnosis of osteonecrosis due to drugs, multiple sites.
Osteonecrosis due to drugs, particularly corticosteroids and bisphosphonates, is a condition characterized by the death of bone tissue due to a lack of blood supply, often affecting multiple sites in the body. This condition can lead to severe pain, joint dysfunction, and potential collapse of the affected bones. The pathophysiology involves the disruption of blood flow to the bone, which can be exacerbated by the use of certain medications that interfere with bone metabolism. Patients may present with symptoms such as localized pain, swelling, and reduced range of motion in the affected joints. Diagnosis typically involves imaging studies such as MRI or X-rays, which can reveal changes in bone density and structure. Treatment options may include medication adjustments, physical therapy, or surgical interventions such as core decompression or joint replacement, depending on the severity and location of the osteonecrosis.
Detailed history of medication use, imaging results, and treatment plans.
Patients presenting with joint pain and a history of corticosteroid use.
Orthopedic surgeons must document the extent of bone involvement and any surgical interventions performed.
Comprehensive medication history, including duration and dosage of drugs that may cause osteonecrosis.
Patients with autoimmune disorders on long-term corticosteroids presenting with joint symptoms.
Rheumatologists should note the relationship between systemic disease management and the risk of osteonecrosis.
Used for pain management in patients with osteonecrosis.
Document the joint involved and the reason for the procedure.
Orthopedic specialists should ensure that the procedure is justified based on the patient's symptoms.
Corticosteroids and bisphosphonates are the most commonly associated medications, but other drugs such as certain chemotherapy agents can also contribute.
